Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is in a strong position to succeed, as evidenced by their clinical focus on key factors driving chronic inflammatory diseases, with initial programs targeting chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Their pipeline products, EVO756 and EVO301, show promise and potential based on their unique mechanisms of action and positive early signals in clinical trials. Evommune's focus on overlooked indications like migraine and their webinar showcasing the company's potential may bring even more value to their already strong market opportunity.

Bears say

Evommune is a clinical-stage biotechnology company with potential in three main diseases: chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). However, with a focus on only one pipeline product (EVO756) and limited data for its efficacy in CSU, the company may struggle to compete against established biologics and small molecules in the market. In addition, Evommune's current focus on progressing a drug to market and its lack of attention towards sustainability suggests potential difficulties in sustaining long-term growth and profitability.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.